Official Title
Urinary Biomarkers (TIMP-2 and IGFBP7) for Early Diagnostic Assessment of Acute Kidney Injury in Patients With SARS-CoV-2 (COVID-19)
Brief Summary

Among patients with SARS-CoV-2 pneumonia, approximately 20% have an acute kidney injury (AKI) and 5% require renal replacement therapy. Occurrence of AKI in patients with COVID-19 is associated with increased morbidity and mortality. Early detection of patients at risk of AKI would allow to prevent onset or worsening of AKI. The aim of this study is to determine if urine biomarkers of renal tubular damage such as TIMP-2 and IGFBP7 could early identify patients with SARS-CoV-2 pneumonia at risk of developing AKI.

Completed
COVID-19
Renal Replacement Therapy
Acute Kidney Injury

Other: [TIMP-2]*[IGFBP-7]

[TIMP-2]*[IGFBP-7] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital

Eligibility Criteria

Inclusion criteria:

- Age ≥ 18 years

- COVID-19 confirmed by positive SARS-CoV-2 PCR

- at least one urine sample

Exclusion criteria:

- Persons under protection

- Paritcipation rejections

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 100 Years
Countries
France
Locations

Uhmontpellier
Montpellier, France

Romaric Larcher, MD, PharmD, MSc, Principal Investigator
UH Montpellier

University Hospital, Montpellier
NCT Number
Keywords
Acute Kidney Injury
SARS-CoV-2
Renal Replacement Therapy
MeSH Terms
COVID-19
Acute Kidney Injury